Louis B Nabors III MD
Neurooncology
Professor, Neurology, University of Alabama at Birmingham School of Medicine
Join to view full profile
1717 6th Ave SBirmingham, AL 35233
Phone+1 800-822-8816
Fax+1 205-975-7546
Dr. Nabors is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Louis Nabors III, MD, is a neurologist based in Birmingham, AL, with a subspecialty in neuro-oncology. He completed his neurology residency at the University of Alabama Medical Center and an internal medicine internship at the National Capital Consortium. He holds extensive experience in general neurology, neuro-oncology, speech and language disorders, and neuroimaging. Dr. Nabors has contributed to various publications, focusing on glioblastoma and other neuro-oncological topics and has been involved in numerous clinical trials related to glioblastoma and medulloblastoma. He has received CMS Meaningful Use Stage 1 Certification from multiple healthcare systems.
Education & Training
University of Alabama Medical CenterResidency, Neurology, 1995 - 1998
National Capital ConsortiumInternship, Internal Medicine, 1991 - 1992
University of Tennessee Health Science Center College of MedicineClass of 1991
Certifications & Licensure
AL State Medical License 1995 - 2026
FL State Medical License 1994 - 1996
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MyHealth@UABMedicine, UAB Health System, 2013-2014
- CMS Meaningful Use Stage 1 Certification HealthSentry, Cerner Corporation, 2013-2014
- CMS Meaningful Use Stage 1 Certification Powerchart and Cerner Healthe, Cerner Corporation, 2013-2014
Clinical Trials
Publications & Presentations
PubMed
- HuB/HuR inhibition decreases HPV E6 and E7 proteins, stabilizes p53, and induces integrated stress to impair cervical cancer cell growth.Xisheng Liu, Saroj Kumar Shrestha, Yvonne J K Edwards, Natalia Filippova, Charles N Landen
Proceedings of the National Academy of Sciences of the United States of America. 2026-09-01 - Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase-Expressing Lentivect...Louis B Nabors, Mina Lobbous, Xiaosi Han, John Fiveash, Antonio Di Stasi
Journal of Clinical Oncology. 2026-08-10 - EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma.Arifa Nayab, Nouman Mughal, Meher Angez, Sansi Xing, Aarohan M Burma
Science Translational Medicine. 2026-07-08
Journal Articles
- Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed GlioblastomaLouis B Nabors, April Eichler, Clinical Cancer Research
Grant Support
- ELAVL1 role in glioblastoma heterogeneity through intercellular gene transfer mediated by cell fusion and tunneling membrane nanotube formationUNIVERSITY OF ALABAMA AT BIRMINGHAM2023–2028
- ELAVL1 role in glioblastoma heterogeneity through intercellular gene transfer mediated by cell fusion and tunneling membrane nanotube formationUNIVERSITY OF ALABAMA AT BIRMINGHAM2023–2028
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
